About
MedAnnex is a clinical-stage biopharmaceutical company developing MDX-124, a monoclonal antibody targeting annexin-A1 to inhibit cancer cell proliferation and migration, with ongoing Phase 1b cancer trials and plans for autoimmune disease studies.
Explore MedAnnex's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.